AS+SP | artemether-lumefantrine | |||
---|---|---|---|---|
Age | Observed n (percentage) | Age | Estimated percentage | Basis for calculation* |
1–6 years | 8,882 (28.3%) | 1–5 years | 23.6% | As for AS+SP, less 4.7% to cater for 6 year olds |
7–13 years | 4,814 (15.3%) | 6–8 years | 9.1% | As for AS+SP, plus 4.7% to include 6 year olds, minus 10.9% to exclude 9–13 year olds |
14+ years | 17,742 (56.4%) | 9–12 years | 8.7% | 100% minus the other age categories' % |
 |  | 13+ years | 58.6% | As for AS+SP, plus 2.2% to include 13 year olds |
 | 100% |  | 100% |  |